Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)

This article was originally published on Nasdaq

Intercept Pharmaceuticals, Inc. (ICPT) incurred a loss of 68 cents per share (from continuing operations) in second-quarter 2022, wider than the Zacks Consensus Estimate of a loss of 53 cents.

Responses